Hepion Pharmaceuticals Inc (HEPA)

[Couch]

Here is a look at CTRV's phase 3 study.

This is a multicenter, randomized, double-blind, parallel-group, active controlled comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus valacyclovir administered for 7 days in subjects with uncomplicated AHZ(acute herpes zoster).

https://clinicaltrials.gov/ct2/show?term=CONTRAVIR&rank=3


Estimated Enrollment: 825
Study Start Date: June 2015
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)